Skip to main content
. 2024 Mar 19;31(7):4413–4426. doi: 10.1245/s10434-024-15187-y

Fig. 5.

Fig. 5

Pooled response rates in a all cohorts; b first-line therapy; c no extrahepatic disease; d first-line therapy in patients without extrahepatic disease. HAI-S hepatic artery infusion with systemic chemotherapy; TACE-S transarterial chemoembolization with systemic chemotherapy; TARE-S transarterial radioembolization with systemic chemotherapy; FOLFOX folinic acid, 5-flourouracil, oxaliplatin; FOLFIRI folinic acid, 5-fluorouracil, irinotecan; FOLFOXIRI folinic acid, 5-fluorouracil, oxaliplatin, irinotecan; n number of cohorts